|
1
|
Deng GL, Zeng S and Shen H: Chemotherapy
and target therapy for hepatocellular carcinoma: New advances and
challenges. World J Hepatol. 7:787–798. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Toyoda H, Kumada T, Tada T, Sone Y,
Kaneoka Y and Maeda A: Tumor markers for hepatocellular carcinoma:
Simple and significant predictors of outcome in patients with HCC.
Liver Cancer. 4:126–136. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu M, Tang Z, Meng F, Tai M, Zhang J, Wang
R, Liu C and Wu Q: Elevated expression of FoxM1 promotes the tumor
cell proliferation in hepatocellular carcinoma. Tumour Biol.
37:1289–1297. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang Y and Tian Y: miRNA for diagnosis and
clinical implications of human hepatocellular carcinoma. Hepatol
Res. 46:89–99. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsang FH, Au SL, Wei L, Fan DN, Lee JM,
Wong CC, Ng IO and Wong CM: MicroRNA-142-3p and microRNA-142-5p are
downregulated in hepatocellular carcinoma and exhibit synergistic
effects on cell motility. Front Med. 9:331–343. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nishida N and Kudo M: Alteration of
epigenetic profile in human hepatocellular carcinoma and its
clinical implications. Liver Cancer. 3:417–427. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wiley SR, Cassiano L, Lofton T,
Davis-Smith T, Winkles JA, Lindner V, Liu H, Daniel TO, Smith CA
and Fanslow WC: A novel TNF receptor family member binds TWEAK and
is implicated in angiogenesis. Immunity. 15:837–846. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li N, Hu WJ, Shi J, Xue J, Guo WX, Zhang
Y, Guan DX, Liu SP, Cheng YQ, Wu MC, et al: Roles of fibroblast
growth factor-inducible 14 in hepatocellular carcinoma. Asian Pac J
Cancer Prev. 14:3509–3514. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Affò S, Dominguez M, Lozano JJ, Sancho-Bru
P, Rodrigo-Torres D, Morales-Ibanez O, Moreno M, Millán C,
Loaeza-del-Castillo A, Altamirano J, et al: Transcriptome analysis
identifies TNF superfamily receptors as potential therapeutic
targets in alcoholic hepatitis. Gut. 62:452–460. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yin J, Liu YN, Tillman H, Barrett B,
Hewitt S, Ylaya K, Fang L, Lake R, Corey E, Morrissey C, et al:
AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone
metastasis. Cancer Res. 74:4306–4317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang M, Narita S, Tsuchiya N, Ma Z,
Numakura K, Obara T, Tsuruta H, Saito M, Inoue T, Horikawa Y, et
al: Overexpression of Fn14 promotes androgen-independent prostate
cancer progression through MMP-9 and correlates with poor treatment
outcome. Carcinogenesis. 32:1589–1596. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kwon OH, Kim JH, Kim SY and Kim YS:
TWEAK/Fn14 signaling mediates gastric cancer cell resistance to
5-fluorouracil via NF-kB activation. Int J Oncol. 44:583–590.
2014.PubMed/NCBI
|
|
13
|
Zhou H, Hittelman WN, Yagita H, Cheung LH,
Martin SS, Winkles JA and Rosenblum MG: Antitumor activity of a
humanized, bivalent immunotoxin targeting fn14-positive solid
tumors. Cancer Res. 73:4439–4450. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou H, Ekmekcioglu S, Marks JW,
Mohamedali KA, Asrani K, Phillips KK, Brown SA, Cheng E, Weiss MB,
Hittelman WN, et al: The TWEAK receptor Fn14 is a therapeutic
target in melanoma: Immunotoxins targeting Fn14 receptor for
malignant melanoma treatment. J Invest Dermatol. 133:1052–1062.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pan ZQ, Fang ZQ and Lu WL: Characteristics
of gene expression of adrenal cortical steroid synthetase and its
regulatory factor in mice with H22 liver cancer of different
patterns. Zhongguo Zhong Xi Yi Jie He Za Zhi. 31:85–89. 2011.(In
Chinese). PubMed/NCBI
|
|
17
|
Soldan M, Nagel G, Losekam M, Ernst M and
Maser E: Interindividual variability in the expression and NNK
carbonyl reductase activity of 11beta-hydroxysteroid dehydrogenase
1 in human lung. Cancer Lett. 145:49–56. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xiong S, Wang Q, Zheng L, Gao F and Li J:
Identification of candidate molecular markers of nasopharyngeal
carcinoma by tissue microarray and in situ hybridization. Med
Oncol. 28:(Suppl 1). S341–S348. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
L'Espérance S, Popa I, Bachvarova M,
Plante M, Patten N, Wu L, Têtu B and Bachvarov D: Gene expression
profiling of paired ovarian tumors obtained prior to and following
adjuvant chemotherapy: Molecular signatures of chemoresistant
tumors. Int J Oncol. 29:5–24. 2006.PubMed/NCBI
|
|
20
|
Alazami AM, Patel N, Shamseldin HE, Anazi
S, Al-Dosari MS, Alzahrani F, Hijazi H, Alshammari M, Aldahmesh MA,
Salih MA, et al: Accelerating novel candidate gene discovery in
neurogenetic disorders via whole-exome sequencing of prescreened
multiplex consanguineous families. Cell Rep. 10:148–161. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Du H, Zhao T, Ding X and Yan C:
Hepatocyte-Specific expression of human lysosome acid lipase
corrects liver inflammation and tumor metastasis in lal(−/−) mice.
Am J Pathol. 185:2379–2389. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peng HX, Wu WQ, Yang DM, Jing R, Li J,
Zhou FL, Jin YF, Wang SY and Chu YM: Role of B7-H4 siRNA in
proliferation, migration, and invasion of LOVO colorectal carcinoma
cell line. Biomed Res Int. 2015:3269812015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liang XD, Dai YC, Li ZY, Gan MF, Zhang SR,
Yin-Pan Lu HS, Cao XQ, Zheng BJ, Bao LF, et al: Expression and
function analysis of mitotic checkpoint genes identifies TTK as a
potential therapeutic target for human hepatocellular carcinoma.
PLoS One. 9:e977392014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jandova J, Mason CJ, Pawar SC and Watts
GS: Fn14 receptor promotes invasive potential and metastatic
capacity of non-small lung adenocarcinoma cells through the
up-regulation of integrin α6. Neoplasma. 62:41–52. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cheng E, Whitsett TG, Tran NL and Winkles
JA: The TWEAK receptor Fn14 Is an Src-inducible protein and a
positive regulator of Src-driven cell invasion. Mol Cancer Res.
13:575–583. 2015. View Article : Google Scholar : PubMed/NCBI
|
